- Previous Close
165.79 - Open
165.00 - Bid 167.22 x 100
- Ask 173.99 x 100
- Day's Range
163.35 - 175.86 - 52 Week Range
163.35 - 268.30 - Volume
2,157,334 - Avg. Volume
1,198,785 - Market Cap (intraday)
24.389B - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
15.13 - EPS (TTM)
11.06 - Earnings Date Feb 11, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
249.94
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
www.biogen.com7,570
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIIB
View More
Performance Overview: BIIB
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIIB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIIB
View MoreValuation Measures
Market Cap
24.16B
Enterprise Value
29.11B
Trailing P/E
14.99
Forward P/E
9.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.52
Price/Book (mrq)
1.48
Enterprise Value/Revenue
3.03
Enterprise Value/EBITDA
10.41
Financial Highlights
Profitability and Income Statement
Profit Margin
16.81%
Return on Assets (ttm)
4.99%
Return on Equity (ttm)
10.47%
Revenue (ttm)
9.61B
Net Income Avi to Common (ttm)
1.62B
Diluted EPS (ttm)
11.06
Balance Sheet and Cash Flow
Total Cash (mrq)
1.7B
Total Debt/Equity (mrq)
40.66%
Levered Free Cash Flow (ttm)
2.03B
Research Analysis: BIIB
View MoreCompany Insights: BIIB
BIIB does not have Company Insights
Research Reports: BIIB
View MoreBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetBUY as company raises earnings guidance
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.
RatingPrice TargetIt's red, white, blue, and green on Wall Street at midday. The major indices
It's red, white, blue, and green on Wall Street at midday. The major indices are higher. The 10-year Treasury note is up 5 bps at 4.36%. Oil is up 1% at $72 per barrel. Argus has done historical research and found that November is the best month of the year for stocks. Since 1980, November has been up by an average of 2.1%, above the averages for other months. Performance is even better in election years. In the 11 election-year Novembers since 1980, stocks have climbed, on average, 2.6%.